An open-label, multicenter, multiarm, phase 1b study (GO30140, NCT02715531) assessed the efficacy and safety of the combination of atezolizumab (anti-PD-L1 mAb) and bevacizumab (anti-VEGF mAb) in patients with unresectable HCC who had not received any previous systemic therapy [69]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.